Published in Ther Clin Risk Manag on August 16, 2014
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | NCT01234311
Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer (PROTECT) | NCT00779402
The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther (2015) 0.82
Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Mol Cancer Res (2015) 0.78
Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth. Prostate (2016) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist (2007) 4.01
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin (1972) 3.35
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol (2013) 2.88
The current state of hormonal therapy for prostate cancer. CA Cancer J Clin (2002) 2.74
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer (2009) 2.64
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res (2009) 2.62
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol (2014) 2.46
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol (2013) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (1998) 2.15
Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res (2014) 2.10
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol (2012) 2.07
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res (2005) 2.04
Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol (2005) 1.95
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol (1998) 1.92
c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol (1995) 1.83
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res (2006) 1.82
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol (2013) 1.76
Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis (1998) 1.73
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology (2004) 1.67
Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res (2011) 1.58
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer (2013) 1.55
Hormonal therapy: historical perspective to future directions. Urology (2003) 1.49
Is there an antiandrogen withdrawal syndrome with enzalutamide? BJU Int (2014) 1.47
A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer (1991) 1.44
Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer (1998) 1.38
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem (2010) 1.36
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res (2013) 1.33
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother (2007) 1.24
Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol (1991) 1.21
Overview of dehydroepiandrosterone biosynthesis. Semin Reprod Med (2004) 1.20
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate (2006) 1.13
Treatment sequencing in metastatic castrate-resistant prostate cancer. Asian J Androl (2014) 1.12
The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin Investig Drugs (2010) 1.11
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer (2009) 1.01
Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs (2009) 0.99
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer (2013) 0.98
The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol (2013) 0.97
Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging (2010) 0.96
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett (2012) 0.95
Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2013) 0.93
Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer (2013) 0.91
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treat Rev (2013) 0.87
(223)Ra targets skeletal metastases and spares normal tissue. Lancet Oncol (2002) 0.87
Age-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigen. J Urol (1986) 0.87
The transcriptional programme of the androgen receptor (AR) in prostate cancer. BJU Int (2014) 0.85
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol (2013) 0.85
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther (2014) 0.82
Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer. Ann Pharmacother (2014) 0.79
Metastatic castration-resistant prostate cancer: critical review of enzalutamide. Clin Med Insights Oncol (2013) 0.78